Table 1 Baseline characteristics
| Â | Total | CIMP-negative | CIMP-low | CIMP-high | p value* |
|---|---|---|---|---|---|
| Â | N (%) | N (%) | N (%) | N (%) | Â |
Total | 497 (100) | 316 (63.6) | 152 (30.6) | 29 (5.8) | Â |
Age | Â | Â | Â | Â | Â |
 <65 years | 348 (70.0) | 222 (70.3) | 108 (71.1) | 18 (62.1) | 0.34 |
 ≥65 years | 149 (30.0) | 94 (29.7) | 44 (28.9) | 11 (37.9) |  |
Sex | Â | Â | Â | Â | Â |
 Male | 301 (60.6) | 201 (63.6) | 88 (57.9) | 12 (41.4) | 0.029 |
 Female | 196 (39.4) | 115 (36.4) | 64 (42.1) | 17 (58.6) |  |
Location | Â | Â | Â | Â | Â |
 Proximal | 169 (34.0) | 87 (27.5) | 61 (40.1) | 21 (72.4) | <0.001 |
 Distal | 328 (66.0) | 229 (72.5) | 91 (59.9) | 8 (27.6) |  |
BMI | Â | Â | Â | Â | Â |
 <25 kg/m2 | 323 (65.0) | 197 (62.3) | 103 (67.8) | 23 (79.9) | 0.096 |
 ≥25 kg/m2 | 174 (35.0) | 119 (37.7) | 49 (32.2) | 6 (20.7) |  |
T stage | Â | Â | Â | Â | Â |
 T1–3 | 424 (85.3) | 274 (86.7) | 128 (84.2) | 22 (75.9) | 0.14 |
 T4 | 73 (14.7) | 42 (13.3) | 24 (15.8) | 7 (24.1) |  |
N stage | Â | Â | Â | Â | Â |
 N0–1 | 364 (73.2) | 228 (72.2) | 116 (76.3) | 20 (69.0) | 0.59 |
 N2 | 133 (26.8) | 88 (27.8) | 36 (23.7) | 9 (31.0) |  |
Tumor stage | Â | Â | Â | Â | |
 II, high-risk | 74 (14.9) | 48 (15.2) | 21 (13.8) | 5 (17.2) | 0.71 |
 III | 423 (85.1) | 268 (84.8) | 131 (86.2) | 24 (82.8) |  |
Histology | Â | Â | Â | Â | Â |
 MAC | 25 (5.0) | 7 (2.2) | 12 (7.9) | 6 (20.7) | <0.001 |
 Non-MAC | 472 (95.0) | 309 (97.8) | 140 (92,1) | 23 (79.3) |  |
Microsatellite status (N = 495) |  |  |  | ||
 MSS/MSI-L | 463 (93.5) | 306 (97.5) | 138 (90.8) | 19 (65.5) | <0.001 |
 MSI-H | 32 (6.5) | 8 (2.5) | 14 (9.2) | 10 (34.5) |  |
KRAS mutation (N = 383) |  |  |  |  | |
 Wild type | 280 (73.1) | 185 (76.4) | 77 (64.2) | 18 (85.7) | 0.18 |
 Mutation | 103 (26.9) | 57 (23.6) | 43 (35.8) | 3 (14.3) |  |
BRAF mutation (N = 423) |  | ||||
 Wild type | 407 (96.2) | 270 (99.3) | 122 (93.8) | 15 (71.4) | <0.001 |
 Mutation | 16 (3.8) | 2 (0.7) | 8 (6.2) | 6 (28.6) |  |